FOXA2 suppression by TRIM36 was found to exert an anti-cancer function in colorectal cancer (CRC) by promoting NRF2/GPX4-mediated ferroptosis, emphasizing the potential of targeting the Nrf2/GPX4 pathway for therapeutic interventions in cancer [31,32]. This evidence concerns the gene GPX4 and colorectal cancer.